Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1321 to 1335 of 2208 results for guidelines

  1. Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of systemic anticancer treatments Number NG161

    Research recommendation
    Published
    21 October 2021

  2. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  3. What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    14 July 2022

  4. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

    Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA563

  5. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.

    Technology appraisal guidance
    Published
    13 May 2020
    View recommendations

    Sections for TA629

  6. Geriatric assessment and care:- What is the cost-effectiveness of comprehensive geriatric assessment and care on specialist units compared with alternative models of care on general wards?

    from the US) and evidence from the economic analysis carried out for this guideline suggest that care in a specialist unit is likely to...

    Research recommendation
    Published
    29 January 2016

  7. Relaxation and biofeedback:- What is the effect of relaxation and biofeedback therapies on [Irritable bowel syndrome] (IBS) symptoms and patient-related outcomes?

    not sufficient to make recommendations. Patient representation in the Guideline Development Group supports this view, from a personal...

    Research recommendation
    Published
    9 June 2015

  8. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    Any explanatory notes(if applicable) Why this is important: This guideline has established that atorvastatin 20 mg is clinically and...

    Research recommendation
    Published
    9 June 2015

  9. Using mental capacity assessment tools to assess capacity:- What is the accuracy and/or effectiveness, cost effectiveness and acceptability of mental capacity assessment tools that are compliant with the Mental Capacity Act 2005?

    mental capacity as outlined in the Mental Capacity Act 2005. Although the guideline committee reviewed some evidence evaluating the...

    Research recommendation
    Published
    18 December 2018

  10. Natural history of varicose veins:- In people with varicose veins at CEAP (Clinical, etiological, anatomical and pathophysiological) stage C2 or C3, what are the factors that influence progression of the disease to CEAP stages C5 or C6?

    notes(if applicable) Why this is important:- The evidence review for the guideline showed a lack of high-quality evidence on the...

    Research recommendation
    Published
    9 June 2015

  11. Board members

    Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.

  12. Imaging options in occult hip fracture: In people with a continuing suspicion of a hip fracture but whose radiographs are normal, what is the clinical and cost effectiveness of CT compared with MRI, in confirming or excluding the fracture?

    Any explanatory notes(if applicable) Why this is important:The Guideline Development Group's consensus decision to recommend CT over a...

    Research recommendation
    Published
    3 February 2023

  13. Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination treatment with a cholinesterase inhibitor and memantine for people with Parkinson's disease dementia if treatment with a cholinesterase inhibitor alone is not effective or no longer effective?

    Any explanatory notes(if applicable) Why this is important:- The guideline committee felt that cholinesterase inhibitors, memantine and...

    Research recommendation
    Published
    15 October 2018

  14. Preferred place of care and place of death:- When planning and managing end of life care, what factors help children and young people with life-limiting conditions and their parents or carers to decide where they would like end of life care to be provided and where they prefer to die?

    parents and carers is that their child is able to die at home. However, the guideline committee's experience suggests that there are...

    Research recommendation
    Published
    15 February 2017

  15. Training:- What are the effects of different approaches to home care training on outcomes for people who use home care services?

    to both practitioners and people using the services. Reviews for this guideline found a lack of evidence on the impact of home...

    Research recommendation
    Published
    13 October 2015